scout

April 2019

At the 2019 American Society of Clinical Oncology–Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium, Natalie Vokes, MD, MPhil, reviews the latest evidence linking tumor mutational burden to outcome in patients treated with immune checkpoint blockade as well as genomic correlates of response within the tumor immunity cycle.

The success of chimeric antigen receptor T-cell therapy observed in hematologic malignancies has not yet translated into the solid tumor setting; however, efforts continue to try to bring this new modality into the treatment paradigm for solid tumors, including pancreatic cancer.